Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 47, 2014, Pages 16830-16835

  Li, Xuanwen ^a   Fries, Susanne ^a   Li, Ruizhi ^b   Lawson, John A ^a   Propert, Kathleen J ^a,c   Diamond, Scott L ^b   Blair, Ian A ^a   FitzGerald, Garret A ^a   Grosser, Tilo ^a  

^a Institute of Translational Medicine and Therapeutics   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acetylation; Aspirin; Cyclooxygenase; MS; Nonsteroidal antiinflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSSOVER PROCEDURE; ENZYME ACTIVITY; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROFLUIDIC ANALYSIS; NORMAL HUMAN; PROTEIN ACETYLATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; ACETYLATION; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MICROFLUIDICS; THROMBOCYTE;

ACETYLATION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; HUMANS; MICROFLUIDICS;

EID: 84913580142     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1406997111     Document Type: Article

References (34)

1. Institute of Medicine (2011) Relieving Pain in America. A Blueprint for Transforming Prevention, Care, Education and Research (National Academy Press, Washington, DC).
2. Baigent C, et al.; Antithrombotic Trialists' (ATT) Collaboration (2009) Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849-1860.
3. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 116(1):4-15.
4. Grosser T, Yu Y, FitzGerald GA (2010) Emotion recollected in tranquility: Lessons learned from the COX-2 saga. Annu Rev Med 61:17-33.
5. Kearney PM, et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. BMJ 332(7553):1302-1308.
6. Coxib and Traditional NSAID Trialists' (CNT) Collaboration; Bhala N, et al. (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769-779.
7. Becker MC, et al.; PRECISION Investigators (2009) Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 157(4):606-612.
8. Macdonald TM, Mackenzie IS, Wei L, Hawkey CJ, Ford I; SCOT study group collaborators (2013) Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal antiinflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: Protocol of the standard care versus celecoxib outcome trial (SCOT). BMJ Open 3(1):e002295.
9. Ouellet M, Riendeau D, Percival MD (2001) A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci USA 98(25):14583-14588.
10. Rimon G, et al. (2010) Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc Natl Acad Sci USA 107(1):28-33.
11. Catella-Lawson F, et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809-1817.
12. Rosenstock M, Danon A, Rubin M, Rimon G (2001) Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal antiinflammatory drugs. Eur J Pharmacol 412(1):101-108.
13. Capone ML, et al. (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45(8):1295-1301.
14. Gladding PA, et al. (2008) The antiplatelet effect of six non-steroidal antiinflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101(7):1060-1063.
15. Hohlfeld T, et al. (2008) Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 6(1): 166-173.
16. Anzellotti P, et al. (2011) Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences. Arthritis Rheum 63(3):850-859.
17. Galliard-Grigioni KS, Reinhart WH (2009) A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. Eur J Pharmacol 609(1-3):96-99.
18. Angiolillo DJ, Hwang C, Datto C, Desai B, Sostek M (2011) Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: A phase I, randomized, double-blind, placebo-controlled, noninferiority trial. Clin Ther 33(12):1883-1893.
19. Reilly IA, FitzGerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 69(1):180-186.
20. Capone ML, et al. (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 82(1-4):85-94.
21. Zhou Y, Boudreau DM, Freedman AN (2014) Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf 23(1):43-50.
22. Farkouh ME, et al.; TARGET Study Group (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet 364(9435):675-684.
23. Cannon CP, et al.; MEDAL Steering Committee (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet 368(9549):1771-1781.
24. Silverstein FE, et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284(10):1247-1255.
25. Ciccimaro E, Hanks SK, Yu KH, Blair IA (2009) Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography/mass spectrometry. Anal Chem 81(9):3304-3313.
26. 2 production in healthy subjects. Thromb Res 17(3-4):317-327.
27. Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311(19):1206-1211.
28. Grosser T, et al. (2013) Drug resistance and pseudoresistance: An unintended consequence of enteric coating aspirin. Circulation 127(3):377-385.
29. Fries S, et al. (2006) Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130(1):55-64.
30. Palazzini E, Galli G, Babbini M (1990) Multiple-dose pharmacokinetics of naproxen from a controlled-release tablet in healthy volunteers. Int J Clin Pharmacol Res 10(5): 277-284.
31. Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP, Vree JB, Guelen PJ (1993) Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Biopharm Drug Dispos 14(6):491-502.
32. Couzin J (2005) Drug testing. Massive trial of Celebrex seeks to settle safety concerns. Science 310(5756):1890-1891.
33. Lucitt MB, et al. (2008) Analysis of the zebrafish proteome during embryonic development. Mol Cell Proteomics 7(5):981-994.
34. Li R, Fries S, Li X, Grosser T, Diamond SL (2013) Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirin. Clin Chem 59(8):1195-1204.